Skip to content

Study · Animal study (in vivo) · pig · 2009

12 results

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE

Journal of the American College of Cardiology1 Feb 2009Cited by 361 (Europe PMC)

PMID19195607 (opens in a new tab)DOI10.1016/j.jacc.2008.10.033 (opens in a new tab)PepBankPUB-19195607
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with ischemia-reperfusion injury, exenatide reduced myocardial infarct size versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide reduced heart infarct size compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMyocardial infarct size
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Myocardial infarct size
    32.7%
    exenatide
    Myocardial infarct size
    53.6%
    PBS

    Source sentences

    Summary
    Exenatide reduced myocardial infarct size (32.7 +/- 6.4% vs. 53.6 +/- 3.9%; p = 0.031)
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with ischemia-reperfusion injury, exenatide preserved systolic wall thickening versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide preserved systolic wall thickening compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSystolic wall thickening
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Systolic wall thickening
    47.3%
    exenatide
    Systolic wall thickening
    8.1%
    PBS

    Source sentences

    Summary
    and prevented deterioration of systolic and diastolic cardiac function (systolic wall thickening: 47.3 +/- 6.3% vs. 8.1 +/- 1.9%, p < 0.001;
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with ischemia-reperfusion injury, exenatide reduced myocardial stiffness versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide reduced heart muscle stiffness compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMyocardial stiffness
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Myocardial stiffness
    0.12 mm Hg/ml
    exenatide
    Myocardial stiffness
    0.22 mm Hg/ml
    PBS

    Source sentences

    Summary
    myocardial stiffness: 0.12 +/- 0.06 mm Hg/ml vs. 0.22 +/- 0.07 mm Hg/ml; p = 0.004).
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide increased myocardial phosphorylated Akt versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide increased phosphorylated Akt in the heart compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMyocardial phosphorylated Akt
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide increased myocardial Bcl-2 expression versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide increased Bcl-2 expression in the heart compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMyocardial Bcl-2 expression
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide reduced active caspase 3 expression versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide reduced active caspase 3 expression compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseActive caspase 3 expression
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide reduced TUNEL-positive cells versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide reduced cells with DNA damage compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTUNEL-positive cells
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, fewer cells were terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling-positive.
    2 context sentences
    Summary · context
    After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower.
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide reduced nuclear oxidative stress versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide reduced nuclear oxidative stress compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNuclear oxidative stress
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, nuclear oxidative stress as assessed with an 8-hydroxydeoxyguanosine staining was reduced in the exenatide treatment arm, and superoxide dismutase activity and catalase activity were increased.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide increased superoxide dismutase activity versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide increased superoxide dismutase activity compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSuperoxide dismutase activity
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, nuclear oxidative stress as assessed with an 8-hydroxydeoxyguanosine staining was reduced in the exenatide treatment arm, and superoxide dismutase activity and catalase activity were increased.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, exenatide increased catalase activity versus phosphate-buffered saline.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide increased catalase activity compared with phosphate-buffered saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCatalase activity
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Comparator
    Phosphate-buffered saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, nuclear oxidative stress as assessed with an 8-hydroxydeoxyguanosine staining was reduced in the exenatide treatment arm, and superoxide dismutase activity and catalase activity were increased.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In pigs with ischemia-reperfusion injury, serum insulin increased after exenatide treatment.

    In plain wordsIn pigs with ischemia-reperfusion injury, serum insulin increased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSerum insulin
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum insulin levels increased after exenatide treatment, without affecting glucose levels.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with ischemia-reperfusion injury, exenatide did not affect glucose levels.

    In plain wordsIn pigs with ischemia-reperfusion injury, exenatide did not change glucose levels.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose levels
    Study

    pign: not reported in source

    Coronary artery ligation and reperfusion injury
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum insulin levels increased after exenatide treatment, without affecting glucose levels.
    1 context sentence
    Summary · context
    Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial pageClinicalTrials.govUpdated 12 Oct 2016
Status unknownNot applicableNCT02650596

Effects of GLP-1 on Chronic Heart Failure

Shi Yangn = 68Jan 2016 to est. Feb 2018

Heart Failure

Trial pageClinicalTrials.govUpdated 8 Jan 2016
Status unknownNot applicableNCT02490176

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Chinese PLA General Hospitaln = 50Jul 2015 to est. Jul 2016

Heart Failure

Trial pageClinicalTrials.govUpdated 29 Feb 2016
Status unknownNot applicableNCT02507128

Effects of Glucagon Like Peptide-1 on No-reflow

Chen Wei Ren, MDn = 190Jul 2015 to est. Jul 2016

Acute ST-segment Elevation Myocardial Infarction

Trial pageClinicalTrials.govUpdated 23 Jul 2015
CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 5 May 2016
CompletedPhase 4NCT01580514

Myocardial Protection of Exenatide in AMI

Kyunghee University Medical Centern = 127Sept 2009 to Aug 2011

Myocardial Infarction

Trial pageClinicalTrials.govUpdated 19 Apr 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.